BioInvent Management's Shareholding after Completion of the Rights Issue
BioInvent International AB (publ) (STO:BINV) has previously announced that members of BioInvent’s management and key personnel have, in addition to existing holdings, purchased subscription rights and subscribed for new shares corresponding to a total of 2.8 per cent of the shares offered in the rights issue completed in May 2015. Following the completion of the rights issue Management’s changes in shareholdings are presented.
|Management's shareholding||Before the rights issue||Changes||After the rights issue|
|Michael Oredsson, CEO||43,000||527,648||570,648|
|Björn Frendéus, Chief Scientific Officer||804||311,168||311,972|
|Per-Anders Johansson, SVP President, Technical Operations||250,300||-||250,300|
|Anna Wickenberg, VP Clinical Development||0||+231,34||231,348|
To the editors:
BioInvent International AB is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer. The company has unique expertise in antibody drug development from initial concept to late clinical phase. The screening tool F.I.R.S.T.TM and the antibody library n-CoDeR® are two patented tools that enable identification of relevant human antibodies and disease targets during the discovery phase. BioInvent has also considerable experience in and a facility for process development and production of antibodies for clinical studies. The scope and strength of this platform is also used to develop antibody-based drugs in collaboration with partners who finance the development of new drugs, and provide BioInvent with the right to milestone payments and royalties on sales. These partners include Bayer Pharma, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Servier, and Xoma. More information is available at www.bioinvent.com.
This information was brought to you by Cision http://news.cision.com
|Wertpapier: BioInvent International|